

2022-020 dated 4 March 2022 and 2022-021 dated 11 March 2022, the Minister also took certain measures to protect the health of the population;

WHEREAS it is expedient to renew the public health emergency for a period of ten days;

IT IS ORDERED, therefore, on the recommendation of the Minister of Health and Social Services:

THAT the public health emergency be renewed until 25 March 2022;

THAT the measures provided for in Orders in Council 177-2020 dated 13 March 2020, 222-2020 dated 20 March 2020, 460-2020 dated 15 April 2020, 505-2020 dated 6 May 2020, 566-2020 dated 27 May 2020, 615-2020 dated 10 June 2020, 651-2020 dated 17 June 2020, 885-2020 dated 19 August 2020, 943-2020 dated 9 September 2020, 964-2020 dated 21 September 2020, 135-2021 dated 17 February 2021, 885-2021 dated 23 June 2021 and 1276-2021 dated 24 September 2021 and by Ministerial Orders 2020-004 dated 15 March 2020, 2020-007 dated 21 March 2020, 2020-008 dated 22 March 2020, 2020-014 dated 2 April 2020, 2020-015 dated 4 April 2020, 2020-016 dated 7 April 2020, 2020-017 dated 8 April 2020, 2020-019 and 2020-020 dated 10 April 2020, 2020-022 dated 15 April 2020, 2020-023 dated 17 April 2020, 2020-026 dated 20 April 2020, 2020-027 dated 22 April 2020, 2020-028 dated 25 April 2020, 2020-029 dated 26 April 2020, 2020-030 dated 29 April 2020, 2020-032 dated 5 May 2020, 2020-033 dated 7 May 2020, 2020-034 dated 9 May 2020, 2020-035 dated 10 May 2020, 2020-037 dated 14 May 2020, 2020-039 dated 22 May 2020, 2020-042 dated 4 June 2020, 2020-044 dated 12 June 2020, 2020-049 dated 4 July 2020, 2020-060 dated 28 August 2020, 2020-061 dated 1 September 2020, 2020-062 dated 4 September 2020, 2020-064 dated 17 September 2020, 2020-067 dated 19 September 2020, 2020-069 dated 22 September 2020, 2020-076 dated 5 October 2020, 2020-087 dated 4 November 2020, 2020-091 dated 13 November 2020, 2020-097 dated 1 December 2020, 2020-099 dated 3 December 2020, 2020-102 dated 9 December 2020, 2020-107 dated 23 December 2020, 2021-003 dated 21 January 2021, 2021-005 dated 28 January 2021, 2021-010 dated 5 March 2021, 2021-017 dated 26 March 2021, 2021-022 dated 7 April 2021, 2021-024 dated 9 April 2021, 2021-027 dated 16 April 2021, 2021-028 dated 17 April 2021, 2021-032 dated 30 April 2021, 2021-036 dated 15 May 2021, 2021-039 dated 28 May 2021 and 2021-040 dated 5 June 2021, 2021-049 dated 1 July 2021, 2021-050 dated 2 July 2021, 2021-051 dated 6 July 2021, 2021-052 dated 7 July 2021, 2021-053 dated 10 July 2021, 2021-054 dated 16 July 2021, 2021-055 dated 30 July 2021, 2021-057 dated 4 August 2021, 2021-058 dated 13 August 2021,

2021-059 dated 18 August 2021, 2021-060 dated 24 August 2021, 2021-061 dated 31 August 2021, 2021-062 dated 3 September 2021, 2021-063 dated 9 September 2021, 2021-065 dated 24 September 2021, 2021-066 dated 1 October 2021, 2021-067 dated 8 October 2021, 2021-069 dated 12 October 2021, 2021-071 and 2021-072 dated 16 October 2021, 2021-073 dated 22 October 2021, 2021-074 dated 25 October 2021, 2021-077 dated 29 October 2021 and 2021-078 dated 2 November 2021, 2021-079, 2021-080 and 2021-081 dated 14 November 2021, 2021-082 dated 17 November 2021, 2021-083 dated 10 December 2021, 2021-085 dated 13 December 2021, 2021-087 dated 14 December 2021, 2021-088 dated 16 December 2021, 2021-089 dated 19 December 2021, 2021-090 dated 20 December 2021, 2021-091 dated 21 December 2021, 2021-092 dated 22 December 2021, 2021-093 dated 23 December 2021, 2021-095 and 2021-096 dated 31 December 2021, 2022-003 and 2022-004 dated 15 January 2022, 2022-005 dated 21 January 2022, 2022-008 dated 23 January 2022, 2022-009 dated 25 January 2022, 2022-010 dated 27 January 2022, 2022-011 dated 29 January 2022, 2022-012 dated 4 February 2022, 2022-013 dated 5 February 2022, 2022-014 dated 7 February 2022, 2022-015 dated 11 February 2022, 2022-018 dated 19 February 2022, 2022-019 dated 25 February 2022, 2022-020 dated 4 March 2022 and 2022-021 dated 11 March 2022, except to the extent that they were amended by those Orders in Council or Ministerial Orders, continue to apply until 25 March 2022 or until the Government or the Minister of Health and Social Services modifies or terminates them;

THAT the Minister of Health and Social Services be empowered to take any measure provided for in subparagraphs 1 to 8 of the first paragraph of section 123 of the Public Health Act (chapter S-2.2).

YVES OUELLET
Clerk of the Conseil exécutif

105599

Gouvernement du Québec

O.C. 318-2022, 16 March 2022

Community pharmacy access program for certain COVID-19 pharmaceutical treatments

WHEREAS, under paragraph *h* of section 3 of the Act respecting the Ministère de la Santé et des Services sociaux (chapter M-19.2) the Minister of Health and Social Services is to promote the development and implementation of programs and services according to the needs of individuals, and families and other groups;

WHEREAS, under the first paragraph of section 2 of the Act respecting the Régie de l'assurance maladie du Québec (chapter R-5) the function of the Board (Régie) is to administer and implement the programs of the health insurance plan instituted by the Health Insurance Act (chapter A-29) and any other program entrusted to it by law or by the Government;

WHEREAS, under the fifteenth paragraph of section 3 of the Health Insurance Act (chapter A-29), the Board assumes the cost of services and goods provided under the programs it administers by virtue of the first paragraph of section 2 of the Act respecting the Régie de l'assurance maladie du Québec according to the conditions and methods provided for under those programs;

WHEREAS, under the first paragraph of section 2.1 of the Act respecting the Régie de l'assurance maladie du Québec the Board is to recover, from the Ministère de la Santé et des Services sociaux or body concerned, the cost of services and goods it assumes under a program entrusted to it by law or by the Government, to the extent provided for under that program;

WHEREAS it is expedient to entrust to the Board the Community pharmacy access program for certain COVID-19 pharmaceutical treatments;

IT IS ORDERED, therefore, on the recommendation of the Minister of Health and Social Services:

THAT the Board be entrusted with the Community pharmacy access program for certain COVID-19 pharmaceutical treatments, attached to this Order in Council.

YVES OUELLET
Clerk of the Conseil exécutif

COMMUNITY PHARMACY ACCESS PROGRAM FOR CERTAIN COVID-19 PHARMACEUTICAL TREATMENTS

1. To be eligible under this program, a person must be a person insured within the meaning of subparagraph g.1 of the first paragraph of section 1 of the Health Insurance Act (chapter A-29), that is, be a resident or temporary resident of Québec who is duly registered with the Régie de l'assurance maladie du Québec, hereafter referred to as the "Board", and produce his or her health insurance card, claim booklet or valid eligibility card to the pharmacist.

Despite the foregoing, insofar as a pharmacist complies with the provisions of the program and special agreement to be entered into between the Minister of Health and Social Services and the Association québécoise des

pharmaciens propriétaires concerning access in community pharmacies to certain COVID-19 pharmaceutical treatments, hereafter referred to as the "special agreement", the pharmacist is entitled to be remunerated by the Board for a service provided to a person, even if the person has not produced his or her health insurance card, claim booklet or eligibility card, in the following circumstances and cases:

(a) the person is a homeless person;

(b) the person ordinarily resides in Québec, or settles in Québec, but is ineligible for health insurance.

2. The pharmaceutical treatments covered by this program are supplied by a pharmacist under a prescription and are intended solely for a person eligible for the program because the person has a condition listed in Schedule A, which must be confirmed in the prescription.

3. The type, cost, format and quantity of pharmaceutical treatments covered by this program are listed in Schedule B to the program.

4. The Minister of Health and Social Services may agree at any time, in an agreement with the Board, to modify the conditions listed in Schedule A and the list of pharmaceutical treatments in Schedule B, in particular to reflect the arrival on the Canadian market of new COVID-19 drug therapies and the recommendations made by the Institut national d'excellence en santé et en services sociaux.

5. The Board assumes only the cost of professional services provided for in the special agreement, at the rate and on the conditions set out in that agreement and, for the pharmaceutical treatments listed in Schedule B, according to the type, format and quantity of pharmaceutical treatments supplied, the wholesaler's profit margin being set at 6.5% of the unit price of the treatments appearing in that Schedule, up to a maximum of \$49 per format.

6. The Minister of Health and Social Services is to reimburse the Board for the sums paid under this program, on such terms and conditions as may be agreed on.

7. For services provided, a pharmacist covered by this program may claim or receive from the Board only the remuneration provided for in the special agreement. In addition, no pharmacist may require any payment whatsoever from an eligible person.

8. No pharmacist or wholesaler who receives pharmaceutical treatments to be distributed pursuant to this program may sell or distribute them otherwise than in connection with the program.

9. Beneficiaries under the program are exempted from the payment of any contribution.

10. Services and goods obtained from outside Québec are not covered by this program except those provided by a pharmacist with whom the Board has entered into a special agreement for that purpose, if the pharmacy is situated in a region bordering on Québec and no Québec pharmacy within a radius of 32 kilometres of the pharmacy serves the public.

11. The Board is to periodically report to the Minister of Health and Social Services on the costs incurred in connection with this program, on such terms and conditions as may be agreed on. The reports are not to contain personal information.

12. The Board is to post this program on its website not later than the day the program takes effect. Any modifications under section 4 are also to be posted on the website not later than the day they take effect, so as to inform the public.

13. This program takes effect on 17 March 2022 and ends on 31 March 2023.

SCHEDULE A

Persons eligible for the program

Paxlovid^{MC} (nirmatrelvir and ritonavir):

A person with COVID-19 (confirmed by NAAT or antigen test) with mild to moderate symptoms for 5 or fewer days, not hospitalized because of COVID-19, who is at high risk of COVID-19 life-threatening complications, from among the **following list**:

—an adult with moderate to severe immunosuppression caused by an underlying condition or its treatment (irrespective of vaccination status);

—an unvaccinated or partially vaccinated person (incomplete primary vaccination) and:

- 60 years of age or older; or
- 18 years of age or older with at least one of the following conditions:
 - hemoglobinopathy;
 - chronic renal failure;
 - chronic hepatic insufficiency;
 - obesity (increased risk with BMI \geq 35);
 - diabetes (increased risk if uncontrolled);

–confirmed high blood pressure (increased risk if uncontrolled);

- atherosclerotic cardiovascular disease;
- heart failure, NYHA functional class II to IV;
- chronic lung disease (ex. COPD, moderate to severe asthma).

—an adolescent weighing at least 40 kg or a pregnant woman:

–with at least one condition entailing a high risk of COVID-19 life-threatening complications from among the above list;

–and who is not adequately protected/vaccinated or a suboptimal vaccination response is anticipated in the clinician's opinion;

–and after discussion with, for example, a specialist in pediatric infectiology or maternal foetal medicine;

—exceptionally, an adult adequately protected/vaccinated with very high risk of COVID-19 complications (ex. very advanced age, several comorbidities among the above list, especially if uncontrolled, and suboptimal protection against the circulating variant, anticipated despite full primary vaccination, after discussion with a specialist physician or an experienced colleague.

SCHEDULE B

Type of pharmaceutical treatments	Unit format	Unit cost	Maximum quantity of units per service
Paxlovid ^{MC} (nirmatrelvir and ritonavir)	1 package containing 20 tablets of nirmatrelvir and 10 tablets of ritonavir	\$800	1

105600

Gouvernement du Québec

O.C. 320-2022, 16 March 2022

Extension of the effect of the Act to establish a perimeter around certain places in order to regulate demonstrations in relation to the COVID-19 pandemic

WHEREAS the Act to establish a perimeter around certain places in order to regulate demonstrations in relation to the COVID-19 pandemic (2021, chapter 26) was assented to on 23 September 2021;